Drug intelligence / Profile preview

elsamitrucin (Bristol Myers Squibb)

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

Elsamitrucin is a semi-synthetic antitumor antibiotic derived from the fermentation of *Actinomadura* species. It functions primarily as a DNA intercalator and a potent inhibitor of topoisomerase II, leading to DNA strand breaks and the inhibition of DNA synthesis. Developed by Bristol Myers Squibb, the compound was investigated in clinical trials for the treatment of various malignancies, including non-Hodgkin lymphoma and solid tumors. However, its clinical development was discontinued due to limited efficacy and toxicity profiles observed in Phase 2 studies.

Other names: elsamitrusinelsamitrucin

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on elsamitrucin (Bristol Myers Squibb).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elsamitrucin (Bristol Myers Squibb).

Explore the full profile